Sad Lamiss Mohamed, Younis Samar Galal, Elity Mohamed Mosad
Tanta University, Tanta, Egypt,
Med Oncol. 2014 Jul;31(7):58. doi: 10.1007/s12032-014-0058-9. Epub 2014 Jun 17.
Systemic therapy improves the survival and quality of life of patients with advanced stage non-small cell lung cancer (NSCLC). Several new therapeutic options have emerged for advanced NSCLC, incorporating novel cytotoxicity agents (taxanes, gemcitabine, pemetrexed) and molecular-targeted agents (erlotinib, bevacizumab) and the optimal prognostic marker for survival remains unclear. The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementation group-1 (ERCC1) in locally advanced NSCLC patients that received cisplatin-based chemotherapy. Clinical data concerning 80 patients with histopathologically confirmed non-small cell lung cancer who are planned to receive cisplatin-based adjuvant chemotherapy were collected. The protein expression levels for ERCC1 are immunohistochemical examined in 80 patients. The relationship between the ERCC1 protein expression level and the clinical outcomes of the patients is then observed. The 3-year survival rate and median survival time of stage III NSCLC received chemotherapy with/without concurrent chemoradiotherapy were 20 % and 10 months, respectively. Survival of patients with ERCC1-negative tumors was significantly longer than those with ERCC1-positive tumors (p = 0.0001). Prognostic factors with overall survival were performance status, cigarette smoking, stage, weight loss and ERCC1. While as regard progression-free survival prognostic factors were stage, weight loss, ERCC1 and degree of positivity of ERCC1 progression. It was found that ERCC1 protein expression might play an important role in the prognosis of locally advanced NSCLC patients treated with cisplatin-based adjuvant chemotherapy.
全身治疗可提高晚期非小细胞肺癌（NSCLC）患者的生存率和生活质量。针对晚期NSCLC已出现了几种新的治疗选择，包括新型细胞毒性药物（紫杉烷类、吉西他滨、培美曲塞）和分子靶向药物（厄洛替尼、贝伐单抗），而生存的最佳预后标志物仍不明确。本研究的目的是评估临床病理特征和切除修复交叉互补组1（ERCC1）在接受以顺铂为基础化疗的局部晚期NSCLC患者中的预后价值。收集了80例经组织病理学确诊为非小细胞肺癌且计划接受以顺铂为基础辅助化疗患者的临床资料。对80例患者进行ERCC1蛋白表达水平的免疫组化检测。然后观察ERCC1蛋白表达水平与患者临床结局之间的关系。接受化疗联合或不联合同步放化疗的Ⅲ期NSCLC患者的3年生存率和中位生存时间分别为20%和10个月。ERCC1阴性肿瘤患者的生存期明显长于ERCC1阳性肿瘤患者（p = 0.0001）。总生存的预后因素有体能状态、吸烟、分期、体重减轻和ERCC1。而无进展生存的预后因素有分期、体重减轻、ERCC1和ERCC1进展阳性程度。研究发现，ERCC1蛋白表达可能在接受以顺铂为基础辅助化疗的局部晚期NSCLC患者的预后中起重要作用。
